Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.70 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19860124 | 0.93 | IMPDH2 (0.59) | IMPDH2PRMT3NOTUMKDM4EALDH1A1 | |
| SCHEMBL19860110 | 0.92 | IMPDH2 (0.59) | IMPDH2PRMT3NOTUMROCK1ROCK2 | |
| SCHEMBL19860125 | 0.88 | PRMT3 (0.71) | IMPDH2PRMT3NOTUMROCK1ROCK2 | |
| SCHEMBL19860106 | 0.88 | ROCK1 (0.57) | IMPDH2PRMT3NOTUMROCK1ROCK2 | |
| SCHEMBL19860123 | 0.88 | IMPDH2 (0.71) | IMPDH2PRMT3NOTUMROCK1ROCK2 | |
| SCHEMBL2163047 | 0.88 | NOTUM (0.65) | IMPDH2PRMT3NOTUMROCK1ROCK2 | |
| SCHEMBL14124375 | 0.88 | ROCK1 (0.59) | IMPDH2PRMT3NOTUMROCK1ROCK2 | |
| SCHEMBL19860126 | 0.86 | PRMT3 (0.65) | IMPDH2PRMT3NOTUMROCK1ROCK2 | |
| SCHEMBL19860042 | 0.86 | MEN1 (0.60) | IMPDH2PRMT3NOTUMROCK2KDM4E | |
| SCHEMBL2162395 | 0.86 | ROCK2 (0.61) | IMPDH2PRMT3NOTUMROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118064-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2009-11-18 | — | — | EP | claimed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | claimed |
| US-10899714-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2118064-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086269-A2 | 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885RECQL 153/4885 |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885RECQL 153/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885RECQL 153/4885 |
| US-10899714-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885RECQL 153/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885RECQL 153/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885RECQL 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.